Guwahati: November 22, 2020. US Food aro Drug Administration (FDA) para koishe ke Regeneron Pharmaceuticals para experimental antibody tawai bona Covid-19 elaj koriboli emergency authorization manishe koishe. etu tawai toh US President Donald Trump ke October moina te novel coroanvirus positive test thura samai tawai toh loishe. Etu tawai lowa beche body te antibodies paboli naroki, hoilebi tai nejor para body te pachaikena raki dey koishe. Regeneron tawai toh tuita(2) monoclonal antibodies- casirivimab aro imdevimab para bona ase koishe.
Bemari manuh co-morbid thaka khan ke tawai thiya beche bhal howa sign thakishe aro etu para Covid-19 bemari hospital te thaka aro emergency medical te jabole be komti kori dey koishe. FDA para statement te koishe ke, antibody tawai toh Covid-19 symptoms komti thaka jawan aro bacha khan 12 umer para oper nemite bhal khobor ase koishe. “etu monoclonal antibody elaj para bahar te bemar howa manuh ke hospital te jabole komti hoi aro health care system logot be kam halka kori dey”, koikena FDA laga commissioner Stephen Hahn para khobor toh janai thishe. Soruh samai Regeneron tawai toh supply komti thakibo keli koile tawai bonaboli toh dhuk ase aro samai besi loi koishe. Hoilebi, company para koishe ke, tai khan para 80,000 tawai toh bemari manuh nemite November moina kotom kora samai paijabo aro 300,000 tawai toh January 2021 saal te paijaboli koishe. Regeneron toh 2nd pharmaceutical company ase ke FDA para emergency samai joboli manishe. 1st tawai toh Eli Lilly thakishe. Etu saal November moina te aro United States te tawai ekta ke manikena ase koishe.
Add Comment